Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers

S.L. Verhaart, Y. Abu-Ghanem, S.F. Mulder, S. Oosting, A. Van Der Veldt, S. Osanto, M.J.B. Aarts, D. Houtsma, F.P.J. Peters, G. Groenewegen, C.M.L. Van Herpen, L.M. Pronk, M. Tascilar, P. Hamberg, M. Los, G. Vreugdenhil, M. Polee, A.J. Ten Tije, J.B.A.G. Haanen, A. Bex*A.J. van den Eertwegh

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Web of Science)
Original languageEnglish
Number of pages16
JournalClinical Genitourinary Cancer
Volume19
Issue number3
DOIs
Publication statusPublished - 1 Jun 2021

Keywords

  • renal cancer
  • Immune
  • checkpoint inhibitor
  • Met-astatic
  • Systemic therapy
  • Second-line therapy
  • RESPONSE CRITERIA
  • CANCER
  • GUIDELINES
  • LYMPHOCYTE
  • EVEROLIMUS
  • THERAPY

Cite this